Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Treosulfan in Metastatic Ocular Melanoma
NCT00168870Phase 2Unknown
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Feb 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gemcitabine in Ocular melanoma (OM) (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Objective Response Rate according to RECIST. Status: unknown.
02
Drugs
gemcitabine
03
Conditions
Ocular melanoma (OM)
Beyond the preview
Go deeper on NCT00168870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00168870.